Skip to main content
. Author manuscript; available in PMC: 2011 Apr 1.
Published in final edited form as: Proteomics Clin Appl. 2010 Feb 3;4(4):362–371. doi: 10.1002/prca.200900119

Figure 3.

Figure 3

Validation in human serum of two of the NAFLD associated proteins identified in liver samples by 2-DE. Changes in protein expression of CPS1 and GRP78 were validated using 15 serum samples of each of the three groups of subjects, (control, steatosis, and NASH). (A). CPS1 and GRP78 were down-regulated in NASH samples. Quantification of the signal has been obtained by densitometric scanning; data obtained were plotted as intensity values. The horizontal bar represents the media of the intensity values. Three replicas of each Western were performed. Student t-test of the densitometric values were calculated in order to asses the significance of the results The p values obtained for each antibody are as follows: CPS1 (steatosis/control p=4×10−2; NASH/control p=7.3×10−13); GRP78 (steatosis/control p=1×10−3; NASH/control p= 1.4×10−7). (B) Representative immunoblot analysis for the evaluation of six representative patients: C1, C2 (controls) S1, S2 (steatosis), N1, N2 (NASH). The expression levels of CPS1 and GRP78 were analyzed using the antibodies described in Materials and Methods. For evaluation of these proteins, 80 μg of protein was loaded onto a 12% SDS-PAGE. As control loading the PVDF membranes were stained with Ponceau staining (data not shown).